CERDULATINIB FOR TREATING MYELOMA
Compositions and methods for treating multiple myeloma (MM), acute myeloid lymphoma (AML) or a myeloproliferative disease (MPD) in a human patient in need thereof. The methods entail administering to the patient an effective amount of cerdulatinib.
1 . A method of treating multiple myeloma (MM), acute myeloid lymphoma (AML) or a myeloproliferative disease (MPD) in a human patient in need thereof, comprising administering to the patient an effective amount of cerdulatinib or a pharmaceutically acceptable salt thereof, wherein the effective amount is from about 5 mg to about 150 mg daily.
2 . The method of claim 1 , wherein the patient is not being treated with fludarabine.
3 . The method of claim 1 , wherein the patient is not being treated with a purine analog.
4 . The method of claim 1 , wherein the patient is not being treated with an agent that interferes with DNA synthesis.
5 . The method of claim 1 , wherein the administration is once daily.
6 . The method of claim 1 , wherein the administration is twice daily.
7 . The method of claim 6 , wherein the effective amount is from about 25 mg to about 65 mg twice daily.
8 . The method of claim 6 , wherein the effective amount is about 30 mg, 35 mg, 40 mg, 45 mg, or 50 mg twice daily.
9 . The method of claim 1 , wherein the patient suffers from an advanced malignancy of MM, AML or MPD.
10 . The method of claim 1 , wherein the patient has relapsed or not responded to a prior chemotherapy.
11 . The method of claim 10 , wherein the patient has failed at least two prior therapies.
12 . The method of claim 1 , wherein the multiple myeloma is a Stage I, Stage II, or Stage III multiple myeloma.
13 . The method of claim 1 , wherein the patient has an albumin level lower than 3.5 mg/dL.
14 . The method of claim 1 , wherein the patient has a B2-microglobulin level from 3.5 to 5 mg/L or greater than 5 mg/t.
15 . The method of claim 1 , wherein the patient has an FGFR3 activation mutation.
16 . The method of claim 1 , wherein the multiple myeloma is Monoclonal Gammopathy of Undetermined Significance (MGUS), Asymptomatic (Smoldering/Indolent) Myeloma, or Symptomatic (Active) Myeloma.
17 . The method of claim 1 , further comprising administering to the patient a second agent.
18 . The method of claim 17 , wherein the second agent is a P90RSK inhibitor.
19 . The method of claim 17 , wherein the second agent is selected from the group consisting of dexamethasone, melphalan, doxorubicin, bortezomib, lenalidomide, prednisone, carmustine, etoposide, cisplatin, vincristine, cyclophosphamide, BI-D1870, and thalidomide.